XXII
22nd Century Group, Inc., an agricultural biotechnology company, focuses on tobacco harm reduction, reduced nicotine tobacco, and enhancing health and wellness through plant science for the life science and consumer products industries. It develops very low nicotine content tobacco and cigarette products under the VLN King and VLN Menthol King names; and SPECTRUM research cigarettes for use in independent clinical studies. The company has collaboration with Keygene N.V. to develop hemp/cannabis plants for exceptional cannabinoid profiles and other superior agronomic traits for medical, therapeutic, and agricultural uses, as well as other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Buffalo, New York.
22nd Century Group, Inc. (XXII) is rated D+ (1.5/5) on Deltasharpe Prism, scored against Consumer Defensive sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (F). The rating has held at D+ for 2 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B+ (3.5) | F (0.6) | D- (0.9) | F (0.1) | C+ (2.6) | D+ (1.5) |
| 2026-11-08 | B+ (3.6) | F (0.6) | D- (0.9) | F (0.1) | C+ (2.5) | D+ (1.5) |
| 2026-11-01 | B+ (3.6) | F (0.5) | D- (1.0) | F (0.1) | C+ (2.5) | D+ (1.5) |
| 2026-10-25 | B+ (3.6) | F (0.5) | D- (1.0) | F (0.1) | C (2.4) | D (1.5) |
| 2026-10-18 | B+ (3.6) | F (0.5) | D- (1.0) | F (0.1) | C (2.4) | D+ (1.5) |